Date: 2015-05-14
Type of information: Nomination
Compound:
Company: Pieris (Germany)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On May 14, 2015, Pieris Pharmaceuticals, a biotechnology company advancing its patented and proprietary Anticalin® biotherapeutic technologies, announced that it has engaged Dr. Holbrook Kohrt, M.D., Ph.D. as Senior Advisor Translational Medicine Immuno-oncology. Pieris has also entered into a collaboration with Dr. Kohrt’s research laboratory. As part of that alliance, Pieris will gain access to the laboratory’s capabilities to better enable the Company to advance its multispecific immuno-oncology drug candidates to in vivo proof of concept, including access to tumor tissue samples and translational mouse tumor models. Additionally, the collaboration will provide a channel for evaluating and in-licensing novel immunomodulatory targets which could serve as the basis for new Anticalin® drug discovery programs. Dr. Kohrt is an Assistant Professor of Medicine, Division of Oncology, at the Stanford University School of Medicine. He is a board certified medical oncologist and internist at the Stanford University Medical Center and is a member of the Stanford Cancer Institute. His research is focused on developing novel therapeutic strategies to enhance anti-tumor immunity and on preclinical models of novel immunomodulatory antibodies. Dr. Kohrt attended Stanford University Medical School as the Baxter Foundation Scholar, Howard Hughes Scholar, and American Society of Hematology Research Fellow. While there, he developed, validated, and nationally implemented a nomogram for risk prediction in early stage breast cancer. He has published 35 articles in peer reviewed scientific journals.
Financial terms:
Latest news:
